19023496

Source:http://linkedlifedata.com/resource/pubmed/id/19023496

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007131, umls-concept:C0087111, umls-concept:C0205132, umls-concept:C0210657, umls-concept:C0246415, umls-concept:C0344211, umls-concept:C0680954, umls-concept:C1135135
pubmed:issue	6
pubmed:dateCreated	2008-11-21
pubmed:abstractText	Evaluate costs and benefits of erlotinib as 2nd or 3rd line treatment of advanced or metastatic nonsmall cell lung cancer (NSCLC) versus docetaxel, pemetrexed and best supportive care.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19023496-19526635
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9813736
pubmed:citationSubset	IM
pubmed:status	MEDLINE
pubmed:issn	0873-2159
pubmed:author	pubmed-author:AlmodôvarTT, pubmed-author:AraújoAA, pubmed-author:BarataFF, pubmed-author:NegreiroFF, pubmed-author:ParentiFF, pubmed-author:PereiraCC, pubmed-author:PereiraHH, pubmed-author:QueirogaHH, pubmed-author:SilvaCC, pubmed-author:Sotto-MayorRR, pubmed-author:TeixeiraEE
pubmed:issnType	Print
pubmed:volume	14
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	803-27
pubmed:meshHeading	pubmed-meshheading:19023496-Clinical Medicine
pubmed:articleTitle	An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.
pubmed:affiliation	Francisco Gentil Portuguese Oncology Institute, Centro do Porto, Medical Oncology Unit, Porto, Portugal.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't